Found it on usenet:! IMMuNis Corp.-IMMC OTCBB: Today, the President of Biotech Holding (BIOHF-OTCBB) announced an extraordinary report about the ongoing successes of
DIAB-II. For those new to IMMC, IMMuNis receive 25% from all Biotech's DIAB-II drug sales outside of China . DIAB-II, an insulin- receptor sensitize class drug, elevates TYPE-II diabetes patients from the harsh and debilitating contradiction attributed from the
commonly prescribed “Glitazone” base drugs. i.e.- Rezulin-SmithKlien Beecham. The Pharmacology of the DIAB-II has made this orally taken drug “THE RAVE” throughout Brazil and other Latin American Countries. Reading between the Lines, Biotech's News
hints some evidence, in the near term, towards some type of participation from Major Pharmaceutical Manufacture(s). IMMC shareholders continue to get stock value
appreciation. REMEMBER: IMMC has NO DEBT, Small public Float around 500,000 share, Dilutions around 7 Million - all restricted from free trade until Dec. 2000 ( Not Dec 1999), low-nominal overhead, and continues to receive support from both shareholders
and the Medical industry. 100,000 DIAB-II prescriptions or 1% of Type-II inflicted in JUST Brazil and Argentina should generate Biotech $20,000,000.00 US per year of which $5,000,000 would be paid to IMMC. HOT! HOT! HOT! IMMC trades on the OTCBB around $1.95 US. Biotech's news can be found at biotechltd.com |
